1.. Introduction {#S5}
================

Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that is making an increasing contribution to the global burden of disease as the population ages \[[@R1]\]. AD pathology is characterized by the accumulation of amyloid-β plaques and tau tangles, ultimately leading to neuronal cell loss. The neurodegeneration associated with AD is believed to start many decades before clinical onset; during this "preclinical" phase, the plaque and tangle loads in the brain increase until a person-specific threshold level is reached and behavioral changes and cognitive impairment become manifest \[[@R2]--[@R4]\]. At present, there are no disease-modifying treatments available, with existing medications only alleviating certain symptoms of AD. A better understanding of the underlying mechanisms precipitating the onset and progression of pathology is required to enable the design of new, more effective medications.

Increased knowledge about the functional complexity of the genome has led to speculation about the role of epigenetic variation in health and disease, including for neurodegenerative diseases such as AD \[[@R5]\]. Two epigenome-wide association studies (EWAS) of AD \[[@R6],[@R7]\] recently identified consistent patterns of DNA methylation associated with neuropathology. Of particular interest was replicated evidence for cortex-specific hypermethylation at multiple 5′-C-phosphate-G-3′ (CpG) sites within *ANK1*, although differences at a number of other loci were identified in one or both studies \[[@R8]\]. One of the previously reported neuropathology-associated differentially methylated positions (DMPs), cg22962123, is located within the *HOXA* gene cluster on chromosome 7 \[[@R7]\]. Here, we present further evidence to support a role for altered DNA methylation in AD-associated neuropathology across an extensive region spanning the *HOXA* gene cluster.

2.. Methods {#S6}
===========

2.1.. Samples and subjects {#S7}
--------------------------

Our discovery (Mount Sinai) cohort consisted of brain tissue from 147 individuals obtained from the Mount Sinai Alzheimer's Disease and Schizophrenia Brain Bank (<http://icahn.mssm.edu/research/labs/neuropathology-and-brain-banking>). From the 147 donors, two cortical regions (prefrontal cortex \[PFC, N = 144\] and superior temporal gyrus \[STG, N = 142\]) were used for the purposes of the study. All samples were dissected by trained specialists, snap-frozen and stored at − 80°C. Further information about the samples is given in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Ethical approval for the project was provided by the University of Exeter Medical School Research Ethics Committee under application number 14/02/041. Genomic DNA was isolated from \~ 100 mg of each dissected brain region using a standard phenol-chloroform extraction protocol and tested for purity and degradation before analysis. For replication purposes, we used previously published EWAS data collected in two independent cohorts on the Illumina Infinium Human Methylation 450K BeadChip (450K array): (1) the "London" (Lunnon et al.) cohort, consisting of PFC, STG, entorhinal cortex, cerebellum (CER), and premortem blood DNA methylation data from 117 individuals from the Medical Research Council London Neurodegenerative Disease Brain Bank \[[@R6]\] and (2) the "Religious Orders Study/Memory and Aging Project (ROS/MAP)" (De Jager et al.) cohort, consisting of PFC DNA methylation data from 740 individuals from the Religious Orders Study and the Rush Memory and Aging Project \[[@R7]\]. All samples were assigned a unique code number for the experiment, which was independent of age, gender, or diagnosis. This code was used throughout the experiment and analysis.

2.2.. Bisulfite treatment and Illumina Infinium BeadArray {#S8}
---------------------------------------------------------

Five hundred nanograms of genomic DNA was sodium bisulfite converted using the EZ-DNA methylation kit (Zymo Research, Orange, CA, USA), and DNA methylation was subsequently quantified using the 450K array (Illumina, USA) with arrays scanned using an Illumina iScan (software version 3.3.28). Samples were processed by tissue and randomized with respect to age and gender. The Illumina 450K array interrogates \>485,000 probes covering 99% of reference sequence (RefSeq) genes, with an average of 17 CpG sites per gene region (distributed across promoter, 5′untranslated region, first exon, gene body, and 3′untranslated regions). It covers 96% of CpG islands, with additional coverage in island shores and their flanking regions.

2.3.. Microarray quality control and data normalization {#S9}
-------------------------------------------------------

Initial quality control of data was conducted using GenomeStudio (version 2011.1) to determine the status of staining, extension, hybridization, target removal, sodium bisulfite conversion, specificity, and nonpolymorphic and negative controls. Probes previously reported to hybridize to multiple genomic regions or containing a singlenucleotide polymorphism at the single base extension site were removed from subsequent analyses \[[@R9],[@R10]\], in addition to the 65 single-nucleotide polymorphisms used for sample identification on the array (total probes removed 72,067). For each probe, DNA methylation levels were indexed by b values, that is, the ratio of the methylated signal divided by the sum of the methylated and unmethylated signal (*M*/\[*M* + *U*\]).

2.4.. Data analysis {#S10}
-------------------

All computations and statistical analyses were performed using R 3.0.2 and Bioconductor 2.13. Signal intensities were imported into R using the *methylumi* package. Initial quality control checks were performed using functions in the *methylumi* package to assess concordance between reported and genotyped gender. Non-CpG single-nucleotide polymorphism probes on the array were also used to confirm that both brain regions were sourced from the same individual where expected. Data were preprocessed and quantile normalized using the *dasen* function as part of the *wateRmelon* package (wateRmelon_1.0.3) \[[@R11]\] within the R statistical analysis environment and batch corrected using the *ComBat* package \[[@R12]\]. Array data for each of the tissues were normalized separately, and initial analyses were performed separately by tissue. Full Illumina 450K array data were available for the discovery (Mount Sinai) and London (Lunnon et al.) cohorts, and thus we were able to estimate neuronal proportions in the data using the R package *CETS* \[[@R13]\]. For the ROS/MAP (De Jager et al.) cohort, we only had Illumina 450K array data for probes in the *HOXA* region and thus could not calculate neuronal proportions. Therefore, the effects of age, gender, and cell type composition were regressed out of the discovery (Mount Sinai) and London (Lunnon et al.) cohorts, whereas the effects of age and gender only were regressed out of the ROS/MAP (De Jager et al.) cohort before subsequent analysis. For identification of DMPs specifically altered with respect to neuropathological measures of AD, we performed a quantitative analysis in which samples were analyzed separately in each brain region using linear regression models with respect to Braak stage, with probes ranked according to *P* values. The genic location of identified DMPs was annotated by GREAT annotation \[[@R14]\]. We have previously established the multiple testing threshold (experiment-wide significance) for EWAS data generated on the Illumina 450K array as *P* \< 2.2 × 10^−7^ \[[@R15]\]. In brief, in this previous study, 5000 permutations were performed repeating a linear regression model for randomly selected groups of cases and controls (N = 675). For each permutation, *P* values from the EWAS were saved and the minimum identified. Across all permutations, the fifth percentile was calculated to generate the 5% of α significance threshold, which was deemed to be *P* \< 2.2 × 10^−7^. To identify differentially methylated regions (DMRs), we identified spatially correlated *P* values in our data using the Python module *comb-p* to group ≥3 spatially correlated CpGs in a 500-bp sliding window \[[@R16]\]. The *coMET* package was used to identify regional comethylation patterns and regional EWAS results \[[@R17]\]. Fisher's combined *P* value analysis was performed in the *MetaDE* package \[[@R18]\], and meta-analysis on correlation and case control status was performed with the *meta* package \[[@R19]\] within R \[[@R20]\]. Data are available for the discovery (Mount Sinai) cohort within Gene Expression Omnibus under accession number GSE80970. The discovery (Mount Sinai) EWAS data set has been previously used to validate the top 100 DMPs nominated in a previously published EWAS \[[@R6]\]. As such, we have not sought to replicate these top 100 DMPs in the present study.

3.. Results {#S11}
===========

3.1.. *Hypermethylation associated with AD neuropathology is observed in a region spanning 48 kb across the* HOXA *gene cluster in the human cortex* {#S12}
----------------------------------------------------------------------------------------------------------------------------------------------------

Our primary analyses focused on matched PFC and STG tissues from 147 individuals ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). We used the 450K array to first quantify DNA methylation in the PFC and identify DMPs associated with the Braak score, a standardized measure of neurofibrillary tangle burden determined at autopsy, controlling for age, gender, and estimated neuronal cell proportion. We identified 10 experiment-wide significant (*P* \< 2.2 × 10^−7^) DMPs ([Table 1](#T1){ref-type="table"} and [Fig. 1A](#F1){ref-type="fig"}), with 78 DMPs associated with Braak stage at a more relaxed threshold of *P* \< 1 × 10^−5^ ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Of these 78 DMPs, nine were located in the *HOXA* gene cluster on chromosome 7, most notably in the vicinity of *HOXA3*, with one *HOXA* DMP reaching experiment-wide significance (cg22962123: *P* = 1.2 × 10^−7^). We next used a sliding window approach (*comb-p* \[[@R16]\]) to identify spatially correlated regions of differential DNA methylation associated with neuropathology; [Table 2](#T2){ref-type="table"} lists DMRs spanning at least three probes with a window size of 500 bp and a Sidak-corrected *P* value \< .05. We identified six closely located DMRs within the *HOXA* gene region, with the most significant DMR in the *HOXA* region spanning seven probes in a 364-bp region within intron 1 of *HOXA3* ([Fig. 1B](#F1){ref-type="fig"}; Sidak-corrected *P* = 1.19 × 10^−9^). Of note, we observed an extended region of neuropathology-associated hypermethylation spanning 48,754 bp from upstream of the *HOXA2* gene to the *HOXA6* gene and covering 208 Illumina 450K array probes ([Fig. 1C](#F1){ref-type="fig"}). Given that DNA methylation at nearby CpG sites can be highly correlated \[[@R21]\], we visualized comethylation patterns between CpG sites within *HOXA3* using *coMET* \[[@R17]\] and observed highly correlated patterns of DNA methylation between CpG sites in this extended region ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). We next sought to test whether neuropathology-associated DNA methylation patterns across this 48,754-bp region were specific to the PFC, using the Illumina 450K array to profile STG samples from the same individuals. In total, seven probes in the region demonstrated significantly increased DNA methylation after correcting for 208 tests (*P* \< 2.4 × 10^−4^), with the top PFC DMP (cg22962123) being similarly hypermethylated with respect to Braak stage ([Fig. 1D](#F1){ref-type="fig"}; PFC: R = 0.36, *P* = 1.2 × 10^−7^; STG: R = 0.28, *P* = 2.78 × 10^−4^). There was an overall consistent pattern of effect sizes across both brain regions for the 208 probes in the *HOXA* neuropathology-associated region ([Fig. 1E](#F1){ref-type="fig"}; R = 0.76, *P* = 2.66 × 10^−40^).

3.2.. Cortical neuropathology-associated hypermethylation in HOXA3 is observed in independent study cohorts {#S13}
-----------------------------------------------------------------------------------------------------------

We next sought to replicate the observation of neuropathology-associated hypermethylation across these 208 probes in two independent, previously published data sets. First, we examined the "London" (Lunnon et al. \[[@R6]\]) data set, comprising Illumina 450K array data generated using matched PFC, STG, entorhinal cortex, CER, and premortem blood samples obtained from 117 donors (described in \[[@R6]\]; Supplementary [Table 1](#T1){ref-type="table"}). We observed a similar pattern of Braak-associated DNA methylation across this 208-probe region in the replication cohort in both the PFC ([Fig. 2A](#F2){ref-type="fig"}) and STG ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}), with a highly correlated effect size between cohorts in both brain regions (PFC: [Fig. 2B](#F2){ref-type="fig"}; R = 0.74, *P* = 2.27 × 10^−37^; STG: [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}; R = 0.68, *P* = 1.87 × 10^−29^)---15 probes in the PFC and 6 probes in the STG reaching our corrected significance threshold (*P* \< 2.4 × 10^−4^). In contrast, no probes in this region reached the corrected significance threshold in the entorhinal cortex ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}), although the effect size was still correlated (R = 0.41, *P* = 1.23 × 10^−9^). Similarly, no probes reached the significance threshold in the CER ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}) or in premortem whole blood collected in a subset (N = 57) of the same individuals ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}), with no correlation of effect sizes in either the CER (R = 0.03, *P* = .639) or blood (R = 0.11, *P* = .138). This indicates that the association may be specific to only particular regions of the cortex.

We subsequently assessed this region in the "ROS/MAP" (De Jager et al.) data set comprising of 740 PFC samples profiled on the Illumina 450K array (as described in De Jager et al. \[[@R7]\]; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}) observing a similar pattern of effects with highly significant neuropathology-associated hypermethylation across probes in the *HOXA* genic region ([Fig. 2C](#F2){ref-type="fig"}), and a significant correlation of effect size with the same 208 probes in the PFC in the discovery cohort ([Fig. 2D](#F2){ref-type="fig"}; R = 0.80, *P* = 2.39 × 10^−48^). A Fisher's combined *P* value of DNA methylation differences across this region in all three PFC data sets confirmed a clearly defined region of significant neuropathology-associated elevated DNA methylation, with many individual DMPs passing the threshold for experiment-wide significance ([Fig. 2E](#F2){ref-type="fig"}), and a consistent pattern of effects across the three cohorts ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). The most significant DMP identified within the *HOXA3* gene in our discovery cohort (cg22962123; [Table 1](#T1){ref-type="table"}) was also the most significant DMP in our Fisher's combined *P* value analysis (*P* = 1 × 10^−20^). A metaanalysis comparing Braak 0 to VI demonstrated increased DNA methylation with respect to Braak stage across all cohorts in the PFC ([Fig. 2F](#F2){ref-type="fig"}; *P* = 3.11 × 10^−18^). Together, our data suggest that DNA hypermethylation across the extended *HOXA* gene region is robustly associated with AD-related neuropathology in both the PFC and STG, with the strongest effects in the vicinity of *HOXA3*.

4.. Discussion {#S14}
==============

We identified an extended region of elevated DNA methylation in the *HOXA* gene cluster that is associated with AD neuropathology, with consistent effects seen across three independent postmortem brain sample cohorts. Although one previous study had demonstrated differential methylation at a single CpG within the *HOXA* gene cluster \[[@R7]\] and another identified a DMR spanning seven CpG sites \[[@R6]\], this represents the first study to illustrate that hypermethylation in this region extends to 208 DMPs, spanning approximately 48.7 Kb. Differential DNA methylation in the *HOXA* gene cluster has been previously reported in blood collected from Down syndrome individuals \[[@R22]\], which is interesting given that many Down syndrome individuals develop AD resulting from an additional copy of the *APP* gene due to trisomy on chromosome 21. The Down syndrome study demonstrated differential DNA methylation in 20 probes largely located within *HOXA2*. Of note, 17 of these probes were significantly hypermethylated in the PFC in our discovery (Mount Sinai) cohort. However, none were differentially methylated in premortem blood in the London (Lunnon et al.) cohort. In the context of other neurodegenerative disorders, one study that investigated microRNAs targeting *HOX* genes in Huntington's disease demonstrated increased levels of micro-RNAs related to *HOXA5*, *HOXA10*, *HOXA11*, *HOXA11AS*, *HOXA13*, and *HOTAIRM1* in the PFC in Huntington's disease \[[@R23]\]. Although *HOX* genes encode potent transcription factors that play a critical role in embryonic development \[[@R24]\], a recent study in *Drosophila* also highlighted a potent protective function for *HOX* genes in neurons, implicating a role in neuroprotection \[[@R25]\]. Interestingly, this study also highlighted how *HOX* genes act to maintain expression of the ankyrin locus, an important observation given our previous finding of altered DNA methylation in *ANK1* in AD \[[@R6]\]. Indeed, to further explore this hypothesis, we examined the correlation between DNA methylation levels at the most significant *HOX* probe identified in the present study (cg22962123) with the two *ANK1* DMPs that we previously identified to be associated with AD neuropathology (cg11823178 and cg05066959) \[[@R6],[@R7]\] in the PFC, identifying a significant correlation with both *ANK1* probes (cg11823178: R = 0.24, *P* = 5.15 × 10^−10^; cg05066959:R = 0.20, *P* = 2.93 × 10^−8^). Although this correlation could reflect the association between both *HOXA3* and *ANK1* probes with Braak stage, it could highlight a novel physiological mechanism, particularly as we still observed significant hypermethylation (*P* =1.67 × 10^−5^) at our top *HOXA* probe (cg22962123), when controlling for levels of DNA methylation in the top *ANK1* probe (cg11823178). Looking to the future, analyses of gene expression levels should be performed to facilitate the interpretation of the DNA methylation differences we observe in *HOXA*. To conclude, this study provides further evidence for altered epigenetic processes in the pathophysiology of AD and suggests that further work on the neuroprotective functions of *HOX* genes is warranted.
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*HOXA3* hypermethylation is associated with neuropathological measures of AD in cortex. (A) A Manhattan plot of association between DNA methylation in the PFC with Braak stage highlights associations at loci across the genome, with a region on chromosome 7 in the *HOXA3* gene showing the greatest number of probes associated with pathology. The red line indicates experiment-wide significance threshold (*P* = 2.2 × 10^−7^), with the green line indicating a more relaxed significance threshold (*P* = 1 × 10^−5^). (B) Using a sliding window approach to identify differentially methylated regions, we identified six within the *HOXA* gene cluster ([Table 2](#T2){ref-type="table"}), with the most significant region spanning 364 bp in the *HOXA3* gene and containing seven CpG sites that showed increased methylation in late-stage AD (Braak stage VI) compared to healthy controls (Braak stage 0). (C) A mini-Manhattan plot across the *HOXA* gene cluster. Highlighted between gray dashed lines is a 48,754-bp region containing 208 probes characterized by neuropathology-associated hypermethylation. Red circles indicate increased DNA methylation in disease (≥1% between Braak 0 and Braak VI), green circles indicate decreased DNA methylation in disease (≥1% between Braak 0 and Braak VI), and black circles indicate DNA methylation differences \<1% between Braak 0 and Braak VI. (D) The site demonstrating the greatest DNA methylation difference (cg22962123) in the PFC (R = 0.36, *P* = 1.2 × 10^−7^) also showed a similar but weaker association in the STG (R = 0.28, *P* = 2.78 × 10^−4^). (E) A quadrant plot of the effect size of the 208 probes identified in the PFC and their corresponding effect size in the STG highlights a significant correlation between brain regions (R = 0.76, *P* = 2.66 × 10^−40^). Abbreviations: AD, Alzheimer's disease; CpG, 5′-C-phosphate-G-3′; PFC, prefrontal cortex; STG, superior temporal gyrus.
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![Replication of neuropathology-associated DNA methylation differences across the *HOXA* gene cluster in additional study cohorts. (A) We identified a consistent pattern of increased DNA methylation across the *HOXA* cluster in the London (Lunnon et al.) cohort in the PFC (B) with a strong correlation in effect size across the 208 probes in the region between data sets (R = 0.74, *P* = 2.24 × 10^−37^). (C) A similar pattern of DNA methylation changes was observed in the PFC in the ROS/MAP (De Jager et al.) cohort, (D) with a strong correlation in effect size across the 208 probes in the region between data sets (R = 0.80, *P* = 2.39 × 10^−48^). (E) A Fisher's combined *P* value meta-analysis of the PFC with respect to Braak stage across all three cohorts showed striking patterns of increased DNA methylation with many probes in the *HOXA3* region reaching experiment-wide significance. (F) The most significant probe identified from the discovery cohort (cg22962123) was also the most significant probe in the meta-analysis (*P* = 3.11 × 10^−18^) and characterized by neuropathology-associated hypermethylation across all three cohorts. In plots (A) and (C) red circles indicate increased DNA methylation in disease (≥1% between Braak 0 and Braak VI), green circles indicate decreased DNA methylation in disease (≥1% between Braak 0 and Braak VI), and black circles indicate DNA methylation differences \<1% between Braak 0 and Braak VI. In plots (A), (C), and (E), the red line indicates experiment-wide significance (*P* = 2.2 × 10^−7^), whereas the blue line indicates significance after correcting for 208 tests (*P* = 2.4 × 10^−4^). In plots (A), (C), and (E), the gray dashed lines indicate the same region across the graphs for reference. These show the probes in the extended DMR. In plot (F), red denotes the PFC and green denotes the STG. Abbreviations: DMR, differentially methylated region; PFC, prefrontal cortex; ROS/MAP, Religious Orders Study/Memory and Aging Project; STG, superior temporal gyrus.](nihms-1516805-f0003){#F2}

###### 

The 10 DMPs associated with Braak stage in the PFC in the discovery (Mount Sinai) cohort that reached experiment-wide significance (*P* \< 2.2 × 10^−7^) are shown, with annotation to chromosomal location (hg19), up/downstream genes (from GREAT annotation), *P* value from our quantitative association model, and corrected DNA methylation difference (Δ) from Braak score 0--VI (as a %). Also shown is the corresponding information in the matched STG samples in the same cohort, and the matched brain regions (PFC, STG) in the London (Lunnon et al.) cohort, demonstrating a nominally significant difference. A list of the 78 top-ranked PFC DMPs at a more relaxed threshold of *P* \< 1 × 10^−5^ is given in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}

                                                                               Discovery (Mount Sinai)cohort   London (Lunnon et al.) cohort                                                 
  ------------ -------------- --------- ------------------ ------------------- ------------------------------- ------------------------------- ------- ----------- ------ ----------- ------ -----------
  cg22867816   4:16081205     PROM1     FGFBP2 (−116347)   PROM1 (+4118)       −3.90                           9.80E--09                       −2.04   5.21E--03   \-     \-          \-     \-
  cg06977285   7:18127468               HDAC9 (−408457)    PRPS1L1 (−59983)    3.66                            2.02E--08                       2.68    1.84E--04   \-     \-          1.88   7.65E--03
  cg05783384   2:218843735              RUFY4 (−90242)     TNS1 (−34885)       7.42                            4.46E--08                       5.55    8.01E--05   3.26   7.76E--03   3.83   6.48E--04
  cg07349815   3:123751269              CCDC14 (−70706)    KALRN (−62258)      5.15                            6.70E--08                       \-      \-          2.15   .02         1.83   7.35E--03
  cg21806242   11:72532891    ATG16L2   ATG16L2 (+7539)    FCHSD2 (+320414)    8.51                            7.02E--08                       5.55    4.08E--04   5.22   3.86E--04   4.62   1.10E--03
  cg03834767   7:90794392     CDK14     FZD1 (−99390)      CDK14 (+455681)     −4.50                           8.13E--08                       \-      \-          \-     \-          \-     \-
  cg13935577   12:107974897   BTBD11    PWP1 (−104611)     BTBD11 (+262708)    9.11                            8.45E--08                       5.27    1.49E--03   4.02   5.10E--03   3.73   .02
  cg27078890   11:128457459   ETS1      ETS1 (−23)                             4.85                            9.86E--08                       \-      \-          2.09   .02         \-     \-
  cg22962123   7:27153605     HOXA3     HOXA2 (−11176)     HOXA3 (+5608)       7.88                            1.20E--07                       5.12    2.78E--04   5.62   2.24E--05   5.18   5.21E--04
  cg26199857   12:54764265    ZNF385A   GPR84 (−5995)      ZNF385A (+20,816)   5.43                            1.87E--07                       4.44    1.02E--03   2.62   .03         \-     \-

Abbreviations: DMP, differentially methylated position; PFC, prefrontal cortex; STG, superior temporal gyrus.

###### 

DMRs associated with Braak stage in the PFC---Shown are all significantly associated regions (Sidak-corrected *P* value \< .05) that contain three or more probes, with chromosomal location (hg19), up/downstream genes, number of probes in the significant region, and Sidak-corrected *P* value

  ----------------------------------------------------------------------------------------------------------------------------------
  Chr     Start         End           Illumina annotation   GREAT annotation                         Number of\   Šidák-corrected\
                                                                                                     probes       *P* value
  ------- ------------- ------------- --------------------- ------------------- -------------------- ------------ ------------------
  Chr11   2,321,770     2,323,247     C11ORF21              TSPAN32 (−734)      C11orf21 (+634)      27           3.20E--11

  Chr7    27,153,580    27,153,944    HOXA3                 HOXA2 (−11332)      HOXA3 (+5452)        7            1.19E--09

  Chr7    27,154,262    27,155,234    HOXA3                 HOXA2 (−12318)      HOXA3 (+4466)        16           4.31E--09

  Chr7    27,169,957    27,171,401    HOXA4                 HOXA4 (−261)                             21           2.13E--08

  Chr11   3,15,908      3,16,456      IFITM1 Closest        IFITM1 (+2329)      IFITM3 (+4868)       5            4.02E--08

  Chr12   58,119,915    58,120,237    AGAP2                 AGAP2 (+11,953)     OS9 (+32,172)        6            1.22E--07

  Chr7    27,183,133    27,184,853    HOXA5/HOXA-AS3        HOXA5 (−706)                             42           2.19E--06

  Chr5    78,985,425    78,985,900    CMYA5                 CMYA5 (−37)                              10           2.31E--06

  Chr19   10,736,006    10,736,448    SLC44A2               SLC44A2 (+293)                           8            3.68E--06

  Chr19   39,086,733    39,087,186    MAP4K1                MAP4K1 (+21,604)    RYR1 (+162490)       4            4.94E--06

  Chr6    10,556,147    10,556,523    GCNT2                 GCNT6 (−77,658)     GCNT2 (+27,746)      3            2.93E--05

  Chr3    194,014,592   194,015,171   GRM2 Closest          CPN2 (+57,175)      HES1 (+160,948)      4            3.24E--05

  Chr4    184,908,351   184,909,018   STOX2                 STOX2 (+82,176)     ENPP6 (+230,429)     8            3.60E--05

  Chr7    27,145,972    27,146,445    HOXA3                 HOXA2 (−3779)                            5            4.11E--05

  Chr17   46,388,390    46,388,465    SKAP1                 SKAP1 (+119,124)    SNX11 (+203,508)     3            4.77E--05

  Chr17   74,475,240    74,475,402    RHBDF2                RHBDF2 (+22,168)    AANAT (+25,888)      5            8.13E--05

  Chr3    51,740,741    51,741,280    GRM2                  GRM2 (−75)                               6            1.93E--04

  Chr17   41,363,502    41,364,121    NBR1/TMEM106A         TMEM106 A (−82)                          11           3.04E--04

  Chr17   43,318,610    43,319,371    FMNL1                 FMNL1 (+19,835)     SPATA32 (+20,488)    6            4.51E--04

  Chr7    158,281,410   158,281,613   PTPRN2                PTPRN2 (+98,859)                         3            4.66E--04

  Chr13   43,565,901    43,566,496    EPSTI1                DNAJC15 (−31,140)   TNFSF11 (+417,910)   9            4.72E--04

  Chr20   57,582,787    57,583,520    CTSZ Closest          CTSZ (−852)                              18           6.82E--04

  Chr19   3,179,545     3,180,035     S1PR4                 NCLN (−5808)        S1PR4 (+1054)        4            7.59E--04

  Chr22   37,608,611    37,608,819    SSTR3 Closest         SSTR3 (−353)                             3            8.84E--04

  Chr13   113,698,408   113,699,016   MCF2L                 F7 (−61,409)        MCF2L (+75,177)      13           9.15E--04

  Chr9    34,457,129    34,457,500    FAM219A               DNAI1 (−1518)                            4            1.05E--03

  Chr17   75,315,081    75,315,567    SEPT9                 TNRC6C (−685,813)   SEPT9 (+37,832)      8            1.28E--03

  Chr16   29,674,618    29,675,214    SPN                   SPN (+336)                               6            1.77E--03

  Chr1    55,246,867    55,247,408    TTC22                 PARS2 (−16,951)     DHCR24 (+105,753)    5            2.45E--03

  Chr12   58,132,558    58,133,008                          AGAP2 (−754)                             3            3.00E--03

  Chr7    27,138,712    27,138,974    HOTAIRM1              HOXA1 (−3250)                            4            3.19E--03

  Chr16   67,686,832    67,687,392    RLTRP                 ACD (+7534)         RLTPR (+8290)        4            3.59E--03

  Chr12   58,129,855    58,130,410    AGAP2                 AGAP2 (+1896)       OS9 (+42,229)        4            4.42E--03

  Chr17   19,314,299    19,314,618    RNF112                RNF112 (−48)                             6            9.80E--03

  Chr15   40,583,227    40,583,422    PLCB2                 PLCB2 (+16,798)     PAK6 (+51,704)       3            .01922

  Chr15   38,988,533    38,988,860    C15ORF53              THBS1 (−884,597)    RASGRP1 (−131,690)   4            .01974

  Chr16   1,482,952     1,483,192     CCDC154 Closest       C16orf91 (−3727)                         3            .02843
  ----------------------------------------------------------------------------------------------------------------------------------

Abbreviations: DMR, differentially methylated region; PFC, prefrontal cortex.

###### RESEARCH IN CONTEXT

1.  Systematic review: We performed an epigenome-wide association study (EWAS) to identify differential DNA methylation associated with Braak stage in a discovery cohort of 147 individuals. A regional analysis identified six differentially methylated regions (DMRs), consisting of \>3 differentially methylated positions (DMPs) with a Sidak-corrected *P* value \<0.05, within the *HOXA* gene cluster. Further investigation highlighted a region of neuropathology-associated hypermethylation spanning \>48kb (208 probes) across the *HOXA* gene cluster.

2.  Interpretation: *HOX* genes encode transcription factors important in neural development. A recent study has provided evidence that *Hox* genes can maintain expression of the *Ank* locus \[[@R25]\], which is particularly interesting given that two previous EWAS have provided robust evidence for differential DNA methylation in AD cortex in the *ANK1* gene \[[@R6],[@R7]\]. A significant correlation of DNA methylation was seen between the most significant *HOX* probe identified in the current study with the two *ANK1* DMPs previously identified \[[@R6],[@R7]\], even when controlling for levels of DNA methylation in *ANK1*.

3.  Future directions: Analyses of gene expression levels should be performed to facilitate the interpretation of the DNA methylation differences we observed in *HOXA* as well as determining whether these DNA methylation changes are a cause or consequence of AD neuropathology.
